Understanding Cyclic Citrullinated Peptide IgG: A Marker for Rheumatoid Arthritis


Understanding Cyclic Citrullinated Peptide IgG

CCP IgG antibodies are unique proteins with a pivotal function within the immune system. They possess the ability to identify and bind to specific proteins, initiating an immune response.

Under ordinary circumstances, CCP IgG antibodies pose no harm. Nevertheless, scientific investigations indicate that an overabundance of these antibodies might result in them misidentifying healthy tissues as foreign invaders, potentially contributing to the onset of rheumatoid arthritis [1,2,5].

Cyclic Citrullinated Peptide IgG and Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune illness that influences the joints, causing tenderness and tightness due to its inflammatory character. It’s known for its inflammatory nature, leading to pain and stiffness [13].

Our bodies generate Immunoglobulin G (IgG) antibodies when cyclic citrullinated peptides are present, suggesting the presence of RA. These antibodies can be found years before symptoms start showing up [3].

One study shows that about 60-70% of patients with RA test positive for these autoantibodies [4].

Citrullination and Rheumatoid Arthritis: A Connection?

Rheumatoid arthritis (RA), one of the most common autoimmune diseases globally, has been closely linked with increased levels of CCP IgG. When your body creates too many CCP antibodies because of an overactive immune system or environmental triggers like smoking or infections – you’re likely looking at RA [5].

This condition results in inflammation and pain in joints due to damage caused by autoantibodies. Citrullinated peptides, particularly cyclic ones can be prime targets [5].

Finding Patterns within Chaos: The Diagnostic Significance

An elevated level of CCP IgGs can serve as a red flag for clinicians diagnosing rheumatoid arthritis. With their high specificity, they can help rule out other forms of arthritis [5].

Some patients with RA may not test positive for CCP IgG. Nevertheless, it’s an important part of the bigger picture in understanding and managing RA effectively.

The Role of Autoantibodies in Rheumatoid Arthritis

In people without RA, proteins inside cells remain untouched by the immune system. In those suffering from this disease though, a process called ‘citrullination’ alters these proteins [6].

This change sparks off a reaction where the body starts seeing them as threats. This triggers the production of anti-citrulline protein antibodies such as CCP-IgGs which attack healthy tissues instead [7].

Detecting Anti-CPP Antibodies Early On

What makes CCP-IgGs special is their high specificity for RA diagnosis. Their presence often indicates more severe disease progression too [8].

Finding them early could mean timely intervention and potentially slowing down disease progression. This is why research into CCP-IgGs and their role in RA diagnosis and management continues to be of high importance [8].

Diagnostic Significance of Cyclic Citrullinated Peptide IgG

This leads us to ask: why use CCP IgG and not other markers? The answer lies in its specificity. When compared to the traditional rheumatoid factor (RF), CCP IgGs are much better at confirming RA diagnosis due to their high specificity rate – close to 98% [9]. 

More on Cyclic Citrullinated Peptide IgG for Arthritis

Another intriguing development highlighted how manipulating levels of CCP might affect disease symptoms. The team injected lab rats with modified versions of the peptide and observed changes in their arthritis symptoms. This hinted at potential new therapeutic strategies targeting these peptides [10].

A key point raised by several studies is about timing – early detection using tests like those for CCP can make significant differences in managing Rheumatoid Arthritis effectively. These findings underline why ongoing research into understanding peptides like CCP is so important – they open doors not just for diagnosis but also for treatment possibilities [8].

  • Detection: High levels suggest potential future development of RA [8]
  • Treatment response: Different therapy effectiveness based on concentration [8]
  • Prediction: Concentration changes might signal flare-ups or remission periods [8]

This valuable information has started paving the way towards personalized medicine in treating RA – an approach where each patient’s unique biochemistry guides their treatment plan instead of one-size-fits-all solutions.

FAQs About Cyclic Citrullinated Peptide IgG

The cyclic citrullinated peptide antibody IgG test is used to diagnose rheumatoid arthritis (RA) and is part of the anti-cyclic citrullinated peptide (anti-CCP) antibodies blood test. It helps identify the presence of specific antibodies that target citrullinated peptides, which are associated with RA and connective tissue diseases [8]. 

CCP antibodies can be detected in up to 10%–15% of patients with systemic lupus erythematosus (SLE). Therefore, it is possible that some individuals with lupus will test positive for CCP [11].

Additional tests, such as X-rays, MRI, ultrasound, ESR and CRP tests may be needed alongside the CCP IgG test to confirm a diagnosis of rheumatoid arthritis [14].

A CCP IgG test is a simple blood test. A small amount of blood is drawn from a vein in the arm and sent to a laboratory for analysis [15].


As research advances, our understanding of Cyclic Citrullinated Peptide IgG deepens. Studies are now being conducted to better comprehend CCP-IgG and how it could potentially revolutionize the way we approach treating Rheumatoid Arthritis.

Innovative studies have started exploring if modulating the levels of CCP-IgG in patients can influence disease progression. These findings suggested that decreasing these antibody levels might help control inflammation and joint damage in RA patients [12].

Beyond diagnosis and treatment modulation, researchers see potential in leveraging CCP-IgGs as predictive markers for disease severity or response to specific treatments. This personalized medicine approach may allow physicians to design more targeted therapies based on individual patient profiles [3].

For more information on Cyclic Citrullinate Peptide IgG contact a doctor from our database.

Scientific Research References:

1. Verpoort, K. N., Jol‐Van Der Zijde, C. M., Papendrecht‐Van Der Voort, E. A. M., Ioan‐Facsinay, A., Drijfhout, J. W., Van Tol, M. J. D., … & Toes, R. E. M. (2006). Isotype distribution of anti–cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 54(12), 3799-3808.

2. György, B., Tóth, E., Tarcsa, E., Falus, A., & Buzás, E. I. (2006). Citrullination: a posttranslational modification in health and disease. The international journal of biochemistry & cell biology38(10), 1662-1677.

4. Van Gaalen, F. A., Linn‐Rasker, S. P., Van Venrooij, W. J., De Jong, B. A., Breedveld, F. C., Verweij, C. L., … & Huizinga, T. W. J. (2004). Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis & Rheumatism50(3), 709-715.

5. Pramod, G. R., Dihingia, P., Jha, A. K., Gadgade, A., & Agarwal, D. (2022). Rheumatoid arthritis co-relation with anti-CCP antibodies with special reference to its prevalence in asymptomatic first-degree relatives. Mediterranean Journal of Rheumatology33(1), 42.

6. E Witalison, E., R Thompson, P., & J Hofseth, L. (2015). Protein arginine deiminases and associated citrullination: physiological functions and diseases associated with dysregulation. Current drug targets, 16(7), 700-710.

7. Raptopoulou, A., Sidiropoulos, P., Katsouraki, M., & Boumpas, D. T. (2007). Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts. Critical reviews in clinical laboratory sciences, 44(4), 339-363.

8. Mikuls, T. R., O’Dell, J. R., Stoner, J. A., Parrish, L. A., Arend, W. P., Norris, J. M., & Holers, V. M. (2004). Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti–cyclic citrullinated peptide antibody. Arthritis & Rheumatism50(12), 3776-3782.

9.  Nishimura, K., Sugiyama, D., Kogata, Y., Tsuji, G., Nakazawa, T., Kawano, S., … & Kumagai, S. (2007). Meta-analysis: diagnostic accuracy of anti–cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Annals of internal medicine146(11), 797-808.

11. Kakumanu, P., Sobel, E. S., Narain, S., Li, Y., Akaogi, J., Yamasaki, Y., … & Satoh, M. (2009). Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. The Journal of rheumatology36(12), 2682-2690.

12. Sokolove, J., Johnson, D. S., Lahey, L. J., Wagner, C. A., Cheng, D., Thiele, G. M., … & Robinson, W. H. (2014). Rheumatoid factor as a potentiator of anti–citrullinated protein antibody–mediated inflammation in rheumatoid arthritis. Arthritis & rheumatology66(4), 813-821

13. Grassi, W., De Angelis, R., Lamanna, G., & Cervini, C. (1998). The clinical features of rheumatoid arthritis. European journal of radiology27, S18-S24.

14. Arslan, A., Farooq, S. M. Y., Sugrah, S. K. T., Gilani, S. A., Iqbal, A., Gilani, H. S. A., … & Manzoor, M. (2022). Ultrasonographic assessment of rheumatoid arthritis: A systematic review. The Professional Medical Journal, 29(08), 1181-1190.

About the Author

You may also like these